These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37245962)

  • 1. A nested case-control study of factors contributing to the development of medication-related osteonecrosis of the jaw in patients using bone resorption inhibitors in Mishima City.
    Seki K; Kamimoto A; Wada M; Iinuma T
    J Oral Sci; 2023 Jul; 65(3):184-189. PubMed ID: 37245962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A real-world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with Denosumab.
    Bracchi P; Zecca E; Brunelli C; Miceli R; Tinè G; Maniezzo M; Lo Dico S; Caputo M; Shkodra M; Caraceni AT
    Cancer Med; 2023 Sep; 12(17):18317-18326. PubMed ID: 37559413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth extraction a risk factor?
    Soutome S; Hayashida S; Funahara M; Sakamoto Y; Kojima Y; Yanamoto S; Umeda M
    PLoS One; 2018; 13(7):e0201343. PubMed ID: 30048523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis.
    Ikesue H; Doi K; Morimoto M; Hirabatake M; Muroi N; Yamamoto S; Takenobu T; Hashida T
    Support Care Cancer; 2022 Mar; 30(3):2341-2348. PubMed ID: 34738163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
    Svejda B; Muschitz Ch; Gruber R; Brandtner Ch; Svejda Ch; Gasser RW; Santler G; Dimai HP
    Wien Med Wochenschr; 2016 Feb; 166(1-2):68-74. PubMed ID: 26847441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medication-Related Osteonecrosis of the Jaw in Cancer Patients: Result from the OneFlorida Clinical Research Consortium.
    Yang G; Williams R; Wang L; Farhadfar N; Chen Y; Loiacono AT; Bian J; Holliday LS; Katz J; Gong Y
    J Bone Miner Res; 2022 Dec; 37(12):2466-2471. PubMed ID: 36151778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infection as an Important Factor in Medication-Related Osteonecrosis of the Jaw (MRONJ).
    Otto S; Aljohani S; Fliefel R; Ecke S; Ristow O; Burian E; Troeltzsch M; Pautke C; Ehrenfeld M
    Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34065104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.
    Owosho AA; Liang STY; Sax AZ; Wu K; Yom SK; Huryn JM; Estilo CL
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 May; 125(5):440-445. PubMed ID: 29580668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review.
    Kawahara M; Kuroshima S; Sawase T
    Int J Implant Dent; 2021 May; 7(1):47. PubMed ID: 33987769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis.
    Bagan J; Peydró A; Calvo J; Leopoldo M; Jiménez Y; Bagan L
    Oral Dis; 2016 May; 22(4):324-9. PubMed ID: 26818808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medication-Related Osteonecrosis of the Jaws and CDK4/6 Inhibitors: A Recent Association.
    Marcianò A; Guzzo GM; Peditto M; Picone A; Oteri G
    Int J Environ Res Public Health; 2020 Dec; 17(24):. PubMed ID: 33353034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study.
    Hasegawa T; Hayashida S; Kondo E; Takeda Y; Miyamoto H; Kawaoka Y; Ueda N; Iwata E; Nakahara H; Kobayashi M; Soutome S; Yamada SI; Tojyo I; Kojima Y; Umeda M; Fujita S; Kurita H; Shibuya Y; Kirita T; Komori T;
    Osteoporos Int; 2019 Jan; 30(1):231-239. PubMed ID: 30406309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases.
    Otto S; Pautke C; Van den Wyngaert T; Niepel D; Schiødt M
    Cancer Treat Rev; 2018 Sep; 69():177-187. PubMed ID: 30055439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases.
    Ikesue H; Mouri M; Tomita H; Hirabatake M; Ikemura M; Muroi N; Yamamoto S; Takenobu T; Tomii K; Kawakita M; Katoh H; Ishikawa T; Yasui H; Hashida T
    Support Care Cancer; 2021 Aug; 29(8):4763-4772. PubMed ID: 33527228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab.
    Wick A; Bankosegger P; Otto S; Hohlweg-Majert B; Steiner T; Probst F; Ristow O; Pautke C
    Clin Oral Investig; 2022 Mar; 26(3):2839-2852. PubMed ID: 34812959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ).
    Fusco V; Campisi G; Bedogni A
    Support Care Cancer; 2022 Sep; 30(9):7047-7051. PubMed ID: 35312858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment.
    Nicolatou-Galitis O; Schiødt M; Mendes RA; Ripamonti C; Hope S; Drudge-Coates L; Niepel D; Van den Wyngaert T
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2019 Feb; 127(2):117-135. PubMed ID: 30393090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Study of Oral Health Parameters and the Properties and Composition of Saliva in Oncological Patients with and without Medication-Related Osteonecrosis of the Jaw Who Take Bisphosphonates.
    Sobczak-Jaskow H; Kochańska B; Drogoszewska B
    Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374277
    [No Abstract]   [Full Text] [Related]  

  • 19. Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study.
    Kajizono M; Sada H; Sugiura Y; Soga Y; Kitamura Y; Matsuoka J; Sendo T
    Biol Pharm Bull; 2015; 38(12):1850-5. PubMed ID: 26632176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases.
    Ikesue H; Doi K; Morimoto M; Hirabatake M; Muroi N; Yamamoto S; Takenobu T; Hashida T
    Cancer Chemother Pharmacol; 2021 Jun; 87(6):871-877. PubMed ID: 33791853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.